Arzerra ofatumumalo

Bitte aktivieren Sie Javascript für eine optimale Darstellung



Drug: Arzerra
Indication: chronic lymphocytic leukemia
Company: GlaxoSmithKline
Date Approved: Oct. 26

Scoop: Arzerra is designed to attach to the CD20 molecule found on B cells, which are vulnerable to leukemia. It flags the cells for destruction, much like Rituxan does, though it uses a different mechanism. Arzerra is also undergoing clinical trials for rheumatoid arthritis. It was also in testing for non-Hodgkin's lymphoma, but produced underwhelming results for that indication. GSK licensed the drug, also known as ofatumumab or HuMax CD-20, in 2007 for $2.1 billion.

No comments:

Post a Comment